Compare Kimberly Clark Corp (KMB) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Tilray Brands Inc — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Kimberly Clark Corp is far larger — about 61.3× Tilray Brands Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Tilray Brands Inc for 31 Days on average.
| KMB | TLRY | |
|---|---|---|
Market Cap | $32.51B | $530.54M |
Volume | 6,139,913 | 9,099,075 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $21.00 |
52-Week Low | $93.05 | $3.57 |
Typical Hold Time | 93 Days | 31 Days |
Enterprise Value | $38.07B | $684.46M |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q2 2026 miss but beats in prior quarters, while revenue declined to $16.45B in 2025. The company maintains a strong dividend yield of over 5% with 54 consecutive years of increases, but cash flow trends raise sustainability questions amid its pending Kenvue acquisition.
KMB offers value with a P/E of 19.32 and analyst consensus target of $117.25, implying 20% upside, but risks include integration challenges from the Kenvue deal, litigation liabilities, and pressured cash flows. The stock's high ROE of 129.43% signals efficient capital use, yet investor sentiment is cautious due to near-term execution hurdles.
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
